A inform poster actually picked this recently in a top rated post............"Based on the observed reduction in mortality and morbidity in this Phase 3 trial, Mesoblast intends to meet with the FDA to discuss a potential approval pathway".
Ann: Rexlemestrocel Reduces Heart Attacks/Strokes/CV Death in CHF, page-8
-
- There are more pages in this discussion • 284 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$2.31 |
Change
-0.100(4.15%) |
Mkt cap ! $2.956B | |||
| Open | High | Low | Value | Volume |
| $2.33 | $2.35 | $2.15 | $30.94M | 13.57M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 75954 | $2.30 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.32 | 10350 | 2 |
View Market Depth
| Last trade - 16.17pm 21/07/2025 (20 minute delay) ? |
| MSB (ASX) Chart |